Baseline | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | |
Placebo | n=16 | n=16 | n=16 | n=16 | n=15 | n=16 | n=16 |
61.3±9.7 | −0.1±1.3 | 0.0±1.5 | 0.3±1.6 | −0.4±1.8 | −0.3±2.7 | 0.2±3.1 | |
Teduglutide 0.10 mg/kg/day | n=32 | n=32 | n=31 | n=30 | n=30 | n=29 | n=29 |
60.1±10.1 | 0.9±1.5** | 1.1±1.5*** | 1.2±1.8*** | 1.6±2.2*** | 1.6±2.1*** | 1.4±2.5** | |
p Value vs placebo† | 0.69 | 0.06 | 0.03 | 0.38 | 0.009 | 0.01 | 0.18 |
Teduglutide 0.05 mg/kg/day | n=35 | n=35 | n=30 | n=28 | n=30 | n=28 | n=27 |
59.0±8.4 | 1.0±1.5*** | 1.1±1.7*** | 0.8±4.6 | 1.2±2.4* | 1.1±2.7* | 1.2±2.8* | |
p Value vs placebo† | 0.38 | 0.02 | 0.03 | 0.60 | 0.03 | 0.06 | 0.31 |
Values shown are mean±SD.
*p<0.05, **p<0.01, ***p<0.001 vs baseline within the same treatment group (t test).
↵† p Value vs placebo for pairwise treatment differences from a general linear model (GLM) method with changes from baseline in corresponding variables as dependent variables and treatment as the main effect, and baseline values of corresponding variables and baseline parenteral consumption levels (indicator variable) as covariates.